Drugs / recombinant human insulin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01334151 | Mar → Aug 2011 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06473662 | Oct 2018 → Jul 2020 | type 2 diabetes mellitus | Roger New | Completed | Met primary |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT00320099 | Jan 2006 → Jan 2009 | infectious disease with sepsis | University of Versailles | Completed | Missed primary |
| Phase 3 | NCT00004984 | Feb 1994 → Jun 2003 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT05089942 | Dec 2021 | type 1 diabetes mellitus, type 2 diabetes mellitus | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human insulin | “Capsule containing 75iu recombinant human insulin administered two times per day” NCT06473662 ↗4“Capsules oral insulin, 7.5 mg of recombinant human insulin crystals” NCT00004984 ↗ |
| Known as | ZJSRM2021 | “Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021” NCT05089942 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human insulin” NCT00320099 ↗ |
| Route | Subcutaneous | “Subcutaneous injections of recombinant human ultralente insulin” NCT00004984 ↗ |